If Expansion Cohort 2.1 has been completed with tolerable toxicity, enrollment in Expansion Cohort 2.2 (EC2.2) will commence at a dose of 0.5 mL PV-10 per cc Lv (up to a maximum dose of 15 mL PV-10). If none or 1 of the first 3 subjects enrolled experiences a DLT, the cohort will be expanded to 6 subjects. If no more than 1 subject among 6 experiences a DLT, the dose of 0.5 mL PV-10 per cc Lv will be judged to be the maximum tolerable dose (MTD) for the study. If 2 or more of the 6 subjects experiences a DLT, the combination of PV-10 and sorafenib at this PV-10 dose level will be judged to be intolerable.